{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:36:48Z","timestamp":1789393008544,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,4]],"date-time":"2012-11-04T00:00:00Z","timestamp":1351987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s10585-012-9548-3","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T10:17:48Z","timestamp":1351937868000},"page":"431-439","source":"Crossref","is-referenced-by-count":22,"title":["Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors"],"prefix":"10.1007","volume":"30","author":[{"given":"George","family":"Pentheroudakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Krikelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Kotoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eti","family":"Meiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Malamou-Mitsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranit","family":"Aharonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,4]]},"reference":[{"key":"9548_CR1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379:1428\u20131435","journal-title":"Lancet"},{"key":"9548_CR2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1634\/theoncologist.12-4-418","volume":"12","author":"G Pentheroudakis","year":"2007","unstructured":"Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418\u2013425","journal-title":"Oncologist"},{"key":"9548_CR3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5858\/134.2.216","volume":"134","author":"FA Monzon","year":"2010","unstructured":"Monzon FA, Koen TJ (2010) Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med 134:216\u2013224","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"9548_CR4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2012.02.002","volume":"84","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G (2012) Long-term survivors among patients with cancer of unknown primary. Crit Rev Oncol Hematol 84(1):85\u201392","journal-title":"Crit Rev Oncol Hematol"},{"key":"9548_CR5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2010.06.003","volume":"37","author":"G Pentheroudakis","year":"2011","unstructured":"Pentheroudakis G, Stoyianni A, Pavlidis N (2011) Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer Treat Rev 37:120\u2013126","journal-title":"Cancer Treat Rev"},{"key":"9548_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.10.003","volume":"75","author":"G Pentheroudakis","year":"2010","unstructured":"Pentheroudakis G, Pavlidis N (2010) Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 75:27\u201342","journal-title":"Crit Rev Oncol Hematol"},{"key":"9548_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0554-3","volume":"119","author":"G Pentheroudakis","year":"2010","unstructured":"Pentheroudakis G, Lazaridis G, Pavlidis N (2010) Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 119:1\u201311","journal-title":"Breast Cancer Res Treat"},{"key":"9548_CR8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1101\/gr.2845604","volume":"14","author":"O Barad","year":"2004","unstructured":"Barad O, Meiri E, Avniel A et al (2004) MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 14:2486\u20132494","journal-title":"Genome Res"},{"key":"9548_CR9","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","volume":"17","author":"GR Varadhachary","year":"2011","unstructured":"Varadhachary GR, Spector Y, Abbruzzese JL et al (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17:4063\u20134070","journal-title":"Clin Cancer Res"},{"key":"9548_CR10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1634\/theoncologist.2011-0466","volume":"17","author":"E Meiri","year":"2012","unstructured":"Meiri E, Mueller WC, Rosenwald S et al (2012) A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 17:801\u2013812","journal-title":"Oncologist"},{"key":"9548_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1750-3639.2008.00184.x","volume":"19","author":"D Nass","year":"2009","unstructured":"Nass D, Rosenwald S, Meiri E et al (2009) MiR-92b and miR-9\/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19:375\u2013383","journal-title":"Brain Pathol"},{"key":"9548_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini Y, Drai D, Elmer G et al (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279\u2013284","journal-title":"Behav Brain Res"},{"key":"9548_CR13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/1471-2407-10-691","volume":"10","author":"KM Clark-Langone","year":"2010","unstructured":"Clark-Langone KM, Sangli C, Krishnakumar J, Watson D (2010) Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 10:691","journal-title":"BMC Cancer"},{"key":"9548_CR14","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2011-0045","volume":"16","author":"JE Joh","year":"2011","unstructured":"Joh JE, Esposito NN, Kiluk JV et al (2011) The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 16:1520\u20131526","journal-title":"Oncologist"},{"key":"9548_CR15","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/JTO.0b013e3181f1900e","volume":"5","author":"MT Agullo-Ortuno","year":"2010","unstructured":"Agullo-Ortuno MT, Lopez-Rios F, Paz-Ares L (2010) Lung cancer genomic signatures. J Thorac Oncol 5:1673\u20131691","journal-title":"J Thorac Oncol"},{"key":"9548_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1755-8794-5-30","volume":"5","author":"RK Laar Van","year":"2012","unstructured":"Van Laar RK (2012) Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer. BMC Med Genomics 5:30","journal-title":"BMC Med Genomics"},{"key":"9548_CR17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","volume":"26","author":"F Cardoso","year":"2008","unstructured":"Cardoso F, Van\u2019t Veer L, Rutgers E et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729\u2013735","journal-title":"J Clin Oncol"},{"key":"9548_CR18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng1060","volume":"33","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49\u201354","journal-title":"Nat Genet"},{"key":"9548_CR19","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/JCO.2006.07.5705","volume":"25","author":"JF Bishop","year":"2007","unstructured":"Bishop JF, Tracey E, Glass P, Jelfs P, Roder D (2007) Prognosis of subtypes of cancer of unknown primary compared to metastatic cancer. J Clin Oncol 25:18S","journal-title":"J Clin Oncol"},{"key":"9548_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1753-6405.2008.00260.x","volume":"32","author":"C Luke","year":"2008","unstructured":"Luke C, Koczwara B, Karapetis C et al (2008) Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health 32:383\u2013389","journal-title":"Aust N Z J Public Health"},{"key":"9548_CR21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdr306","volume":"23","author":"FA Greco","year":"2012","unstructured":"Greco FA, Oien K, Erlander M et al (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23:298\u2013304","journal-title":"Ann Oncol"},{"key":"9548_CR22","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R (2012) Molecular gene expression profiling to predict the tissue of Origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol doi: 10.1200\/JCO2012.43.3755"},{"key":"9548_CR23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2011.06.191","volume":"411","author":"CM Wang","year":"2011","unstructured":"Wang CM, Wang Y, Fan CG et al (2011) miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 411:586\u2013592","journal-title":"Biochem Biophys Res Commun"},{"key":"9548_CR24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2008.377","volume":"23","author":"M Mraz","year":"2009","unstructured":"Mraz M, Malinova K, Kotaskova J et al (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23:1159\u20131163","journal-title":"Leukemia"},{"key":"9548_CR25","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/cddis.2012.98","volume":"3","author":"A Nigro","year":"2012","unstructured":"Nigro A, Menon R, Bergamaschi A et al (2012) MiR-30e and miR-181d control radial glia cell proliferation via HtrA1 modulation. Cell Death Dis 3:e360","journal-title":"Cell Death Dis"},{"key":"9548_CR26","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1038\/onc.2011.543","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Drakaki A, Iliopoulos D, Struhl K (2012) MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 31:3818\u20133825","journal-title":"Oncogene"},{"key":"9548_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11010-011-0752-2","volume":"352","author":"S Thulasingam","year":"2011","unstructured":"Thulasingam S, Massilamany C, Gangaplara A et al (2011) miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264.7 cells. Mol Cell Biochem 352:181\u2013188","journal-title":"Mol Cell Biochem"},{"key":"9548_CR28","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-09-4104","volume":"70","author":"H Al-Nakhle","year":"2010","unstructured":"Al-Nakhle H, Burns PA, Cummings M et al (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70:4778\u20134784","journal-title":"Cancer Res"},{"key":"9548_CR29","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.1158\/1078-0432.CCR-09-1587","volume":"15","author":"PS Soon","year":"2009","unstructured":"Soon PS, Tacon LJ, Gill AJ et al (2009) miR-195 and miR-483-5p Identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 15:7684\u20137692","journal-title":"Clin Cancer Res"},{"key":"9548_CR30","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1158\/0008-5472.CAN-09-4456","volume":"70","author":"A Veronese","year":"2010","unstructured":"Veronese A, Lupini L, Consiglio J et al (2010) Oncogenic role of miR-483-3p at the IGF2\/483 locus. Cancer Res 70:3140\u20133149","journal-title":"Cancer Res"},{"key":"9548_CR31","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/gb-2008-9-8-r127","volume":"9","author":"N Cloonan","year":"2008","unstructured":"Cloonan N, Brown MK, Steptoe AL et al (2008) The miR-17-5p microRNA is a key regulator of the G1\/S phase cell cycle transition. Genome Biol 9:R127","journal-title":"Genome Biol"},{"key":"9548_CR32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.20946","volume":"51","author":"B Schneider","year":"2012","unstructured":"Schneider B, Nagel S, Ehrentraut S et al (2012) Neoplastic MiR-17\u201392 deregulation at a DNA fragility motif (SIDD). Genes Chromosomes Cancer 51:219\u2013228","journal-title":"Genes Chromosomes Cancer"},{"key":"9548_CR33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jcb.23457","volume":"113","author":"L Li","year":"2012","unstructured":"Li L, Shi JY, Zhu GQ, Shi B (2012) MiR-17\u201392 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells. J Cell Biochem 113:1235\u20131244","journal-title":"J Cell Biochem"},{"key":"9548_CR34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11596-012-1004-8","volume":"32","author":"L Wu","year":"2012","unstructured":"Wu L, Chen Z, Zhang J, Xing Y (2012) Effect of miR-513a-5p on etoposide-stimulating B7\u2013H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technolog Med Sci 32:601\u2013606","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"9548_CR35","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1261\/rna.2225110","volume":"16","author":"LW Lee","year":"2010","unstructured":"Lee LW, Zhang S, Etheridge A et al (2010) Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16:2170\u20132180","journal-title":"RNA"},{"key":"9548_CR36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/138920210791616707","volume":"11","author":"A Ripoli","year":"2010","unstructured":"Ripoli A, Rainaldi G, Rizzo M et al (2010) The fuzzy logic of microRNA regulation: a key to control cell complexity. Curr Genomics 11:350\u2013353","journal-title":"Curr Genomics"},{"key":"9548_CR37","doi-asserted-by":"crossref","unstructured":"Fizazi K, Greco FA, Pavlidis N et al. (2011) Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi64\u201368","DOI":"10.1093\/annonc\/mdr389"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-012-9548-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-012-9548-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T21:06:50Z","timestamp":1643576810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-012-9548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["9548"],"URL":"https:\/\/doi.org\/10.1007\/s10585-012-9548-3","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,4]]}}}